
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is expecting to submit seralutinib's NDA for pulmonary arterial hypertension (PAH) in early September, followed by a potential filing acceptance after a 75-day review and a Prescription Drug User Fee Act (PDUFA) action date in 2027. They have recently completed a convertible note exchange offer and consent solicitation which will provide them with the necessary funding to support their operations through potential approval. Despite the potential dilution from the exchange, Gossamer Bio's focus on a totality-of-evidence NDA filing strategy, along with strong support from key opinion leaders and a broad commercial opportunity, supports a positive outlook on the stock.
Bears say
Gossamer Bio is facing significant challenges as a clinical-stage biopharmaceutical company due to its pipeline being centered primarily on one product, seralutinib, and its potential use in treating PAH. While the CT FRI data and PROSERA trial results have increased enthusiasm surrounding this product, there are concerns about the drug's safety, particularly related to liver enzyme elevations, and its potential for cough as a side effect. These issues may hamper the drug's approval and commercial success, leading to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares